Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.
Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.
Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.
“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.
No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.
The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.
Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.
Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.
Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.
Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.
Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.
Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.
Credit: AI
A new Phase II clinical trial has found that a carefully formulated cannabis-based treatment may help alleviate agitation in people with advanced dementia. The findings offer hope for patients and caregivers who face one of the most distressing symptoms of the disease.
The findings are a result of the LiBBY (Life's End Benefits of cannaBidiol and tetrahYdrocannabinol) trial, that was presented at the Alzheimer's Association International Conference (AAIC) 2026 in London.
Researchers say the treatment, which combines purified tetrahydrocannabinol (THC) and cannabidiol (CBD) in an oral formulation, showed significant improvements compared to a placebo.
The multicenter, randomized, double-blind, placebo-controlled Phase II study enrolled 120 hospice-eligible adults with Alzheimer's disease or other forms of dementia experiencing significant agitation.
Participants received either the THC/CBD formulation or a placebo for 12 weeks. Researchers assessed agitation using the Cohen-Mansfield Agitation Inventory (CMAI) along with clinician evaluations of behavioral improvement.
According to the trial results, participants in the cannabis treatment group experienced significantly greater reductions in agitation than those given a placebo.
Clinician assessments showed improvement in 83.9% of treated participants after two weeks, compared with 30.5% in the placebo group.
By 12 weeks, improvement was seen in 87.2% of treated participants versus 23.6% receiving placebo. Nearly 90% of treated participants showed overall clinical improvement during the study.
The study's lead investigator, Dr. Jacobo Mintzer of the Medical University of South Carolina, said, "These results were extremely impressive and showed a level of response not seen before in clinical trials related to dementia. Rarely do we see close to 90% of patients in a trial respond positively to a new medication."
He added, "Agitation affects many people with late-stage dementia, causing symptoms such as restlessness, aggression, and emotional distress that can profoundly impact patients and their caregivers. Current treatment options are limited and often carry significant side effects."
Also read: Normal Ageing or Alzheimer's? Doctors Explain Six Key Differences to Watch For
Agitation affects the majority of people living with Alzheimer's disease and other dementias, especially in the advanced stages.
Symptoms may include pacing, aggression, yelling, restlessness, irritability, and emotional distress, making day-to-day care increasingly challenging.
It also places a heavy emotional and physical burden on caregivers. Many currently prescribed medications, including antipsychotics and sedatives, may increase the risk of falls, excessive sedation, stroke, or even death in older adults.
A treatment that safely reduces agitation without substantially increasing adverse events could be helpful for the patients as well as caregivers.
Investigators said that the results are the strongest seen so far in clinical trials on agitation in advanced dementia.
Also read: Alzheimer's May Be Detectable Years Before Symptoms, Says Neurology Expert
Dementia is an umbrella term describing a significant decline in mental function that interferes with everyday life. It commonly affects memory, thinking and reasoning abilities and is caused by underlying conditions such as Alzheimer's disease or vascular dementia.
Dementia significantly affects an individual's ability to live independently, work and perform daily activities while placing a substantial burden on families and caregivers.
According to the WHO, dementia costs the global economy an estimated US$1.3 trillion every year, with about half of that amount attributed to unpaid care provided by family members and friends.
Credit: X
Lionel Messi is one of the most iconic football players in the world. What many people don't realize is that his athletic career almost ended before it truly began.
As a child, Messi was diagnosed with Growth Hormone Deficiency (GHD), a rare medical condition that affects normal growth and development.
With the ongoing FIFA fever, his story has sparked renewed interest, particularly because Barcelona helped shape football history.
Growth Hormone Deficiency is a condition in which the pituitary gland does not produce enough growth hormone, a hormone essential for normal growth in children. Without adequate treatment, children with GHD often experience the following symptoms:
While growth is the most noticeable concern, modern treatment allows many children to achieve normal or near-normal adult height if diagnosed early.
Messi himself has spoken in recent interviews about the financial and emotional challenges his family faced during those years.
Doctors recommended regular treatment with synthetic growth hormone, requiring frequent injections over several years.
At the time, growth hormone therapy reportedly cost around $900 to $1,000 per month, an amount that Messi's family could not afford.
Messi's local Argentine club, Newell's Old Boys, initially provided some assistance, but not long-term financial support.
His skills on the field eventually caught the attention of FC Barcelona. The Spanish club agreed to sign the young Argentine and help cover the costs of his medical treatment.
The decision required Messi and his family to relocate from Rosario, Argentina, to Spain, which became one of the most significant turning points in football history.
This remains one of the biggest misconceptions surrounding Messi's football career. Messi received growth hormone therapy as a medically prescribed treatment, not as a performance-enhancing drug.
The treatment was meant to correct a hormone deficiency and allow normal physical development under medical supervision.
Sports medicine experts have long emphasized that therapeutic treatment for Growth Hormone Deficiency is fundamentally different from the illegal misuse of growth hormone for athletic performance.
Today, Growth Hormone Deficiency is a recognized endocrine disorder. When diagnosed early and treated appropriately, many children experience significant improvements in growth and can lead healthy, active lives.
Messi's story is more than a football success story. It underscores the importance of early diagnosis and access to specialized medical care. Pediatricians recommend evaluating children whose height or growth pace consistently falls well below expected levels for their age.
Credit: AI
The U.S. Department of Defense is introducing a new policy that will require military personnel over 30 and above to undergo an annual testosterone deficiency screening as part of their routine Periodic Health Assessment.
Personnel under 30 can choose to be screened voluntarily. Those diagnosed with testosterone deficiency may opt for testosterone replacement therapy (TRT), though treatment will remain voluntary.
Defense Secretary Pete Hegseth made the announcement on Wednesday, saying the military must ensure that troops remain physically and mentally prepared for the demands of modern warfare.
Hegseth said in a video posted on X, "As we know, the modern battlefield is brutal and unrelenting. It requires and demands maximum psychological and mental readiness. I'm authorizing a new screening program for testosterone deficiency for our service members, ensuring you have the right testosterone levels to operate at your absolute best."
"By addressing these health markers early, we're keeping you on the leading edge of lethality and giving you the same level of support that you give this nation: the absolute best."
The Defense Secretary also said the goal extends beyond active military service.
"We owe our warriors the absolute best medical care in the world. Taking care of your long-term health means ensuring you remain strong, resilient, and capable, not just for your next deployment, but for the rest of your life."
Also read: Donald Trump's 'Two Mangled Hands' Spark Fresh Health Speculation
Testosterone is a hormone that plays an important role in maintaining muscle mass, bone density, strength, energy levels, mood and sexual function in men. Levels naturally decline with age, typically beginning around age 30, falling by roughly 1% each year thereafter.
Military experts say service members may face additional risk factors like high operational tempo, chronic stress, sleep deprivation, traumatic brain injury, blast exposure, and prolonged physical exertion.
Army Major Theodore Crisostomo-Wynne, a urologist at Madigan Army Medical Center, previously told an FDA advisory panel that researchers have observed hormonal disruptions among elite military personnel.
"The high operations tempo and high stress that these service members go through can actually decrease testosterone, sometimes acutely and sometimes even in the long term," he said.
Also read: Expert Highlights Key Vitamins To Combat Male Infertility And Boost Reproductive Health
While low testosterone is a genuine medical condition, physicians caution that it should not be diagnosed or treated simply because hormone levels decline with age.
The American Urological Association says a diagnosis requires both symptoms of testosterone deficiency and at least two separate early-morning blood tests confirming low testosterone levels.
Experts also note that testosterone replacement therapy is intended for people with clinically confirmed deficiency, not healthy individuals seeking improved athletic performance or anti-aging benefits.
According to the Endocrine Society, using testosterone without a medical indication may increase the risk of acne, infertility, worsening sleep apnea, and other adverse effects.
Testosterone deficiency, also known as hypogonadism, occurs when the body does not produce enough testosterone to maintain normal bodily functions. Common symptoms of testosterone deficiency include:
A diagnosis requires both symptoms and laboratory confirmation, according to medical guidelines.
© 2024 Bennett, Coleman & Company Limited